Pfizer Inc. (NYSE:PFE) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 0.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,489,020 shares of the biopharmaceutical company's stock after selling 18,274 shares during the period. New York State Common Retirement Fund owned approximately 0.15% of Pfizer worth $215,112,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of PFE. Brighton Jones LLC increased its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Achmea Investment Management B.V. bought a new stake in Pfizer in the 4th quarter valued at $2,812,000. Madison Investment Advisors LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $5,360,000. Finally, Greatmark Investment Partners Inc. bought a new stake in shares of Pfizer in the 4th quarter worth about $230,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Leerink Partners reduced their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. TD Cowen reduced their target price on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a report on Tuesday, April 22nd. Redburn Atlantic reduced their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Stock Down 0.1%

Shares of NYSE PFE traded down $0.02 during midday trading on Wednesday, hitting $24.59. The company's stock had a trading volume of 44,174,346 shares, compared to its average volume of 41,887,818. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business's fifty day simple moving average is $23.95 and its two-hundred day simple moving average is $24.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market capitalization of $139.79 billion, a price-to-earnings ratio of 17.82, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company's revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.00%. Pfizer's payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.